pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice

S Patel; L Guerenne; P Gorombei; N Omidvar; M-H Schlageter; A A Alex; S Ganesan; R West; L Adès; V Mathews; P Krief; M Pla; P Fenaux; C Chomienne; R A Padua

doi:10.1038/bcj.2015.102

pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice

Blood Cancer J. 2015 Dec 11;5(12):e374. doi: 10.1038/bcj.2015.102.

Authors

S Patel^{1

2}, L Guerenne^{1

2}, P Gorombei^{1

2}, N Omidvar³, M-H Schlageter^{1

2

4}, A A Alex⁵, S Ganesan⁵, R West⁶, L Adès^{1

2

4}, V Mathews⁵, P Krief^{1

2}, M Pla^{1

2}, P Fenaux^{1

2

4}, C Chomienne^{1

2

4}, R A Padua^{1

2

4}

Affiliations

¹ Université Paris Diderot, Institut Universitaire d'Hématologie, Unité Mixte de la Recherche de Santé (UMR-S) 1131, Paris, France.
² Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U) 1131, Paris, France.
³ Haematology Department, Cardiff University School of Medicine, Cardiff, UK.
⁴ Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Saint Louis, Paris, France.
⁵ Department of Hematology, Christian Medical College and Hospital, Vellore, India.
⁶ Welsh Heart Research Institute, Cardiff University School of Medicine, Cardiff, UK.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Animals
Arsenic Trioxide
Arsenicals / therapeutic use*
DNA / administration & dosage
Disease Models, Animal
Immunotherapy
Leukemia, Promyelocytic, Acute / therapy*
Mice
Oxides / therapeutic use*
Tretinoin / therapeutic use*

Substances

Adjuvants, Immunologic
Arsenicals
Oxides
Tretinoin
DNA
Arsenic Trioxide

Grants and funding

IA/S/11/2500267/WTDBT_/DBT-Wellcome Trust India Alliance/India